Evidence map›Paper›PMID 40087827›Full record

ArticleThe Journal of physiology2025

Antiarrhythmic effects of mirabegron on ventricular fibrillation in Langendorff-perfused rabbit ventricles.

Xiao Liu, Yen-Ling Sung, Liyang Zhang, Shuai Guo, Minjing Yang, James E Tisdale, Zhenhui Chen, Joshua I Goldhaber, Michael Rubart, Xiaochun Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiao LiuDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-7280-9226
Yen-Ling SungDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Liyang ZhangDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0009-0000-7758-0355
Shuai GuoDepartment of Pediatrics, Indiana University, Indianapolis, IN, USA.
Minjing YangDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
James E TisdaleCollege of Pharmacy, Purdue University, Indianapolis, IN, USA.ORCID 0000-0002-2117-9463
Zhenhui Chenthe Krannert Cardiovascular Research Center and Division of Cardiology, Department of Medicine, Indiana University, Indianapolis, IN, USA.
Joshua I GoldhaberDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael RubartDepartment of Pediatrics, Indiana University, Indianapolis, IN, USA.
Xiaochun LiDepartment of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.
Peng-Sheng ChenDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-4150-5836

Funding

SK Current, beta-3 adrenoceptor activation and Sex Differences in Ventricular ArrhythmogenesisR01HL139829 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI PENG-SHENG CHEN, ZHILIN QU · 2018 to 2026
$4.5M
Critical Sorting Steps and Pathways in the Trafficking of Cardiac Sarcoplasmic Reticulum ProteinsR01HL169877 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Zhenhui Chen · 2023 to 2026
$2.6M
Novel Approaches for Minimizing Drug-Induced QT Interval LengtheningR01HL153114 · NHLBI · PURDUE UNIVERSITY · PI TISDALE, JAMES E. · 2020 to 2024
$2.4M
Using electrical nerve stimulation to control atrial fibrillation.OT2OD028190 · OD · INDIANA UNIVERSITY INDIANAPOLIS · PI CHEN, PENG-SHENG · 2019 to 2021
$2.3M
NHLBI NIH HHS R01 HL139829NHLBI NIH HHS R01 HL153114NHLBI NIH HHS R01 HL169877NIH HHS OT2 OD028190
6 · The paper itself

Abstract

β-3 adrenoceptor (AR) counteracts the β-1 and β-2 ARs and rescues the effects of excessive catecholamines. To test the hypothesis that a β-3 AR agonist (mirabegron) can reverse the effects of isoproterenol (ISO) on ventricular fibrillation (VF), we performed optical mapping studies in six male and six female Langendorff perfused rabbit hearts at baseline and after sequential administration of ISO (100 nm), mirabegron (1000 nm), apamin (100 nm) and washout (Study I). An additional six male and six female hearts were studied with mirabegron doses ranging between 250 and 1000 nm without ISO (Study II). Patch clamp studies in human embryonic kidney 293 cells were performed to determine the effect of mirabegron on the apamin-sensitive small conductance Ca

Indexed as

AcetanilidesAdrenergic beta-3 Receptor AgonistsAnti-Arrhythmia AgentsHeart VentriclesThiazolesVentricular FibrillationAnimalsFemaleHEK293 CellsHumansIsoproterenolMaleRabbitsAcetanilidesAdrenergic beta-3 Receptor AgonistsAnti-Arrhythmia AgentsIsoproterenolmirabegronThiazolesapaminbeta‐3 adrenoceptorIKASion currentsoptical mappingpatch clampsex differencesSK channel

Identifiers

PMID40087827
PMCPMC13063311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.